# South America Nontuberculous Mycobacteria Market > South America Nontuberculous Mycobacteria Market Research Report By Class of Drugs (Oral Antibiotics, IV Antibiotics, Anti Nausea, Nebulized Antibiotics) and By Region (Brazil, Mexico, Argentina, Rest of South America) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 1.7% - **2024:** $ 747.84 Million - **2025:** $ 760.55 Million - **2035:** $ 900 Million - **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Roche Holding AG (CH), BioMérieux SA (FR), Hologic Inc. (US), Qiagen N.V. (NL), Becton Dickinson and Company (US) **Report ID:** MRFR/HC/50868-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-nontuberculous-mycobacteria-market-52627 --- ## Market Summary ## **South America Nontuberculous Mycobacteria Market Overview** As per MRFR analysis, the South America Nontuberculous Mycobacteria Market Size was estimated at 912.19 (USD Million) in 2023. The South America Nontuberculous Mycobacteria Market Industry is expected to grow from 935(USD Million) in 2024 to 1,227 (USD Million) by 2035. The South America Nontuberculous Mycobacteria Market CAGR (growth rate) is expected to be around 2.502% during the forecast period (2025 - 2035). **Key South America Nontuberculous Mycobacteria Market Trends Highlighted** In South America, the Nontuberculous Mycobacteria (NTM) market is experiencing notable shifts driven by several key market drivers. Increasing awareness and diagnosis of NTM diseases among healthcare providers and patients contribute significantly to the growth of this market. Traditional bacteriological techniques are being complemented by advanced molecular diagnostics, which improve detection rates. Additionally, government initiatives focusing on enhancing healthcare infrastructure and funding for disease awareness programs are bolstering the availability of diagnostic and therapeutic options in the region. Opportunities exist for the development of new diagnostic tools and treatment modalities specifically tailored for the South American population.This is essential, given the region's unique climate and environmental conditions that can contribute to NTM prevalence. Furthermore, the rise in research and development activities by local universities and research institutes creates a collaborative environment aimed at discovering novel approaches to combat NTM infections. Partnerships between pharmaceutical companies and local healthcare providers can facilitate better access to treatment options for affected populations. In recent times, there has been a growing trend toward personalized medicine in infectious disease management, including NTM. Personalized approaches may enhance treatment effectiveness and patient outcomes by considering individual genetic, environmental, and lifestyle factors.Furthermore, the South American healthcare system is witnessing an increased investment in awareness campaigns to educate the public about NTM risks and management. As the region continues to prioritize healthcare advancement and disease management, the Nontuberculous Mycobacteria market will likely see further innovations and expansions to meet the needs of patients effectively. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Nontuberculous Mycobacteria Market Drivers** **Increasing Incidence of Lung Diseases** The South America Nontuberculous Mycobacteria Market Industry is expanding due to the increasing prevalence of lung disorders such as Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, which have been related to environmental factors such as pollution, particularly in metropolitan areas. According to the Pan American Health Organization (PAHO), air pollution causes roughly 77,000 fatalities in South America each year, greatly increasing the prevalence of respiratory disorders. This circumstance has resulted in a greater emphasis on recognizing and treating infections caused by nontuberculous mycobacteria, driving up demand for diagnostic and therapeutic goods in the region. As healthcare practitioners become more aware of the complexity of these illnesses, the South America Nontuberculous Mycobacteria Market is projected to grow further, driving the industry ahead. **Rising Research and Development Investments** Another prominent driver of the South America Nontuberculous Mycobacteria Market Industry is the increasing investment in Research and Development (R&D) aimed at understanding the pathogenic behavior of nontuberculous mycobacteria. Government bodies and private organizations are placing greater emphasis on developing new therapeutic options and diagnostic tools. With initiatives supported by organizations like the Brazilian Ministry of Health, which has allocated funding toward infectious disease research, this trend is likely to lead to innovative treatments and improved understanding of the disease.For instance, a report from the Brazilian Society of Infectious Diseases noted a 15% increase in R&D spending in the last three years, indicating a strong commitment towards tackling these infections and signaling potential growth in the market. **Growing Awareness and Screening Initiatives** The South America Nontuberculous Mycobacteria Market Industry is benefiting from increasing awareness around the importance of screening and early detection of nontuberculous mycobacterial infections. Organizations such as the Argentine Society of Respiratory Medicine have implemented various awareness campaigns, emphasizing the need for timely diagnosis and treatment. The rise in chest X-ray and sputum culture screenings has led to a surge in identified cases, with a recorded 20% increase in diagnosed patients across South America in the past five years.These proactive measures are crucial in improving patient outcomes and reducing the public health burden of these infections, thereby fostering market growth. **South America Nontuberculous Mycobacteria Market Segment Insights** **Nontuberculous Mycobacteria Market Class of Drugs Insights** The South America Nontuberculous Mycobacteria Market has been structured into the Class of Drugs segment, which serves as a crucial element in addressing the challenges posed by nontuberculous mycobacterial infections. This segment includes various treatments such as Oral Antibiotics, Intravenous (IV) Antibiotics, Anti Nausea medications, and Nebulized Antibiotics. Oral Antibiotics play a key role due to their convenience and accessibility for patients, allowing for easier compliance and adherence to treatment regimens. Their widespread use highlights the importance of oral dosage forms in tackling infections effectively in the South American region, where healthcare accessibility can vary significantly across countries. Meanwhile, IV Antibiotics are essential for more severe cases, delivering potent therapeutic agents directly into the bloodstream, which proves critical in acute situations where rapid action is needed. The flexibility in treatment provided by this class of drugs reflects the varied nature of nontuberculous mycobacterial diseases, necessitating a tailored approach to therapy. Anti Nausea medications also hold a notable position within this segment, as managing side effects is crucial for improving the overall patient experience and ensuring that patients can continue with their prescribed treatments without undue discomfort.Lastly, Nebulized Antibiotics offer a targeted method of delivering medication directly to the respiratory system, which is particularly important for patients suffering from lung-related infections caused by nontuberculous mycobacteria. The focus on these diverse drug classes underlines their significance in providing comprehensive care for patients and showcases the South America Nontuberculous Mycobacteria Market's adaptability to meet unique healthcare demands. As the market evolves, understanding the dynamics of each class of drugs will be pivotal for stakeholders seeking to navigate the landscape of nontuberculous mycobacterial treatment options effectively. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Nontuberculous Mycobacteria Market Key Players and Competitive Insights** The South America Nontuberculous Mycobacteria market is characterized by an evolving landscape as the healthcare industry increasingly recognizes the significance of nontuberculous mycobacterial infections. These infections pose challenges in diagnostics and treatment, leading to a growing demand for advanced solutions in microbiology. The competition in this market is driven by various factors, including technological advancements in diagnostic tools, increasing investments in research and development, and the need for effective treatment protocols specific to this region. Furthermore, partnerships and collaborations among industry players are becoming increasingly common, enhancing the market dynamics and accessibility of new products and services tailored to local healthcare needs. The competitive insights reflect the strategic positioning of companies vying for a foothold in this niche yet crucial aspect of infectious disease management. Fujifilm has made significant strides in the South America Nontuberculous Mycobacteria market through its innovative diagnostic solutions that address the pressing need for accurate and timely detection of mycobacterial infections. The company leverages cutting-edge imaging technology and molecular diagnostics to stay competitive in this niche market. Fujifilm's strengths lie in its extensive research and development capabilities, which enable it to produce high-quality diagnostic systems that meet regulatory requirements and local market needs. The company also benefits from a strong distribution network in South America, ensuring that its products are readily available to healthcare providers across the region. By focusing on enhancing the user experience with its diagnostic equipment and building strong relationships with healthcare stakeholders, Fujifilm has positioned itself as a reliable player in the ongoing efforts to combat nontuberculous mycobacterial diseases.BD is another important player in the South America Nontuberculous Mycobacteria market, known for its commitment to advancing infectious disease diagnostics. The company offers a range of products and services, including advanced bacterial culture media, automated systems for growing and identifying mycobacterial strains, and rapid diagnostic tests. BD has established a strong market presence through strategic partnerships, local collaborations, and an expansive sales network that supports healthcare providers in achieving better patient outcomes. The company's strengths lie in its robust portfolio of innovative solutions, a focus on sustainability, and a dedication to improving diagnostic accuracy. Understanding regional challenges, BD is continuously engaged in mergers and acquisitions that enhance its capabilities and expand its influence in the South American healthcare ecosystem, thereby contributing to the fight against nontuberculous mycobacterial infections through comprehensive diagnostic approaches. **Key Companies in the South America Nontuberculous Mycobacteria Market Include** - Fujifilm - BD - Bruker - Canon Medical Systems - Merck KGaA - Thermo Fisher Scientific - Agilent Technologies - Cepheid - Roche - Hologic - Abbott - Luminex - bioMérieux - QIAGEN **South America Nontuberculous Mycobacteria Market Industry Developments** The South America Nontuberculous Mycobacteria Market has experienced significant developments recently. In August 2023, Fujifilm announced the expansion of its microbiological diagnostic capabilities in Brazil, enhancing the detection and treatment of nontuberculous mycobacterial infections. In parallel, Merck KGaA has been increasing its collaboration with local research centers in South America for developing tailored diagnostic solutions, recognizing the rising incidence of nontuberculous mycobacterial diseases in the region. The growth potential of the market has attracted major players such as BD and Thermo Fisher Scientific, driving innovation in diagnostic technologies. Recent years have also witnessed a notable increase in investments towards Research and Development for improving diagnostic tools, with the market valuation expected to grow by 15 percent annually until 2025, fueled by rising health awareness and improved healthcare infrastructure throughout South America. Additionally, in July 2022, Roche acquired a local diagnostic company focused on infectious diseases, strengthening its position in the South American market as demand for advanced nontuberculous mycobacterial testing continues to rise. The increase in partnerships and collaborations among key stakeholders further emphasizes the growing significance of this market in public health initiatives across the region. **South America Nontuberculous Mycobacteria Market Segmentation Insights** **Nontuberculous Mycobacteria Market Class of Drugs****Outlook** - Oral Antibiotics - IV Antibiotics - Anti Nausea - Nebulized Antibiotics **Nontuberculous Mycobacteria Market Regional****Outlook** - Brazil - Mexico - Argentina - Rest of South America ## Market Drivers ### Rising Public Health Initiatives Public health initiatives aimed at combating infectious diseases are likely to influence the nontuberculous mycobacteria market in South America. Campaigns focused on education, prevention, and treatment of respiratory infections are becoming more prevalent. These initiatives may lead to increased funding for research and development in the field of nontuberculous mycobacteria, fostering innovation and improving treatment options. As awareness grows, the market could see a surge in demand for both diagnostic and therapeutic products, potentially increasing market size by 10% within the next five years. ### Advancements in Diagnostic Technologies Technological advancements in diagnostic methods are likely to propel the nontuberculous mycobacteria market in South America. Innovations such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) have improved the accuracy and speed of diagnosing nontuberculous mycobacterial infections. These advancements not only enhance patient outcomes but also facilitate early detection, which is crucial for effective treatment. The market for diagnostic tools is projected to grow significantly, with estimates suggesting a valuation of over $200 million by 2027. This growth reflects the increasing reliance on advanced technologies to combat the challenges posed by nontuberculous mycobacteria. ### Emerging Research and Development Activities The surge in research and development activities related to nontuberculous mycobacteria is poised to drive market growth in South America. Academic institutions and pharmaceutical companies are increasingly focusing on understanding the pathogenicity and treatment of these infections. This research is crucial, as it may lead to the discovery of novel therapeutic agents and improved treatment protocols. The investment in R&D is expected to yield a market expansion, with projections indicating a potential increase in market value by over $150 million by 2028. This growth reflects the commitment to addressing the challenges posed by nontuberculous mycobacteria. ### Increasing Incidence of Respiratory Diseases The rising incidence of respiratory diseases in South America appears to be a significant driver for the nontuberculous mycobacteria market. Conditions such as chronic obstructive pulmonary disease (COPD) and asthma have been increasingly reported, leading to a heightened awareness of respiratory health. This trend may correlate with the growing prevalence of nontuberculous mycobacterial infections, which are often misdiagnosed or underreported. As healthcare providers become more vigilant, the demand for diagnostic tools and treatment options in the nontuberculous mycobacteria market is likely to increase. Furthermore, the market could see a potential growth rate of around 8% annually, driven by the need for effective management of these respiratory conditions. ### Growing Investment in Healthcare Infrastructure The ongoing investment in healthcare infrastructure across South America is expected to positively impact the nontuberculous mycacteria market. Governments and private entities are channeling resources into improving healthcare facilities, which includes enhancing laboratory capabilities for diagnosing and treating infections. This investment is crucial, as it may lead to better access to healthcare services, particularly in rural areas where nontuberculous mycobacterial infections are often overlooked. As healthcare systems strengthen, the market could experience a compound annual growth rate (CAGR) of approximately 7% over the next few years, driven by improved healthcare access and quality. ## Future Outlook The [Nontuberculous Mycobacteria Market](https://www.marketresearchfuture.com/reports/nontuberculous-mycobacteria-market-16170) is projected to grow at 1.7% CAGR from 2025 to 2035, driven by increasing awareness and advancements in diagnostic technologies. **New opportunities:** - Development of targeted therapies for specific nontuberculous mycobacterial infections. - Expansion of telehealth services for remote patient monitoring and consultations. - Investment in rapid diagnostic kits to enhance early detection and treatment efficiency. By 2035, the market is expected to demonstrate steady growth, reflecting evolving healthcare needs. ## Segment Insights ### By Class of Drugs: IV Antibiotics (Largest) vs. Oral Antibiotics (Fastest-Growing) The market for classes of drugs in treating nontuberculous mycobacteria shows notable variation in market share among the different segments. IV Antibiotics hold the largest share due to their efficacy and the clinical preference for intravenous administration in severe cases. In contrast, Oral Antibiotics have witnessed a significant surge in usage, making them the fastest-growing segment as they offer convenience and increased patient compliance, contributing to their rising market presence. Growth trends for the nontuberculous mycobacteria market are driven by factors such as the increasing prevalence of nontuberculous mycobacterial infections and the ongoing research and development in antibiotic therapies. Emerging trends indicate a shift towards more effective oral options, while IV treatments continue to be essential for critical cases. The drive for more accessible treatment options is enhancing the adoption of oral antibiotics, diversifying treatment strategies in the region. IV Antibiotics (Dominant) vs. Oral Antibiotics (Emerging) IV Antibiotics represent the dominant class in the treatment of nontuberculous mycobacteria due to their immediate absorption and targeted action in severe infections. They are often preferred in healthcare settings where rapid intervention is crucial. Conversely, Oral Antibiotics are emerging as a key player in the market, favored for their ease of administration and improved adherence among patients. This shift reflects a broader trend towards outpatient care and self-management of infections, enhancing patient accessibility to treatments. Moreover, innovations in formulation are increasing the efficacy of oral treatments, making them a more attractive option for both patients and healthcare providers. ## Regional Market Share Analysis ### Brazil : Robust Growth and Demand Trends Brazil holds a commanding market share of 350.0, representing approximately 54.5% of the South American nontuberculous mycobacteria (NTM) market. Key growth drivers include increasing awareness of NTM infections, advancements in diagnostic technologies, and supportive government initiatives aimed at improving healthcare infrastructure. The demand for NTM diagnostics is rising due to a growing patient population and enhanced screening programs, supported by regulatory policies that promote innovation in medical technologies. ### Mexico : Increasing Awareness and Investment Mexico's nontuberculous mycobacteria market is valued at 150.0, accounting for about 23.1% of the regional market. The growth is driven by rising healthcare investments, increased public awareness of NTM diseases, and the expansion of diagnostic services. Government initiatives are focusing on improving access to healthcare, which is crucial for early diagnosis and treatment. The demand for NTM testing is also influenced by the rising prevalence of respiratory diseases in urban areas. ### Argentina : Focus on Healthcare Improvements Argentina's market for nontuberculous mycobacteria is valued at 120.0, representing approximately 18.5% of the South American market. Key growth drivers include government policies aimed at enhancing healthcare access and the increasing prevalence of NTM infections. The demand for diagnostic services is on the rise, supported by local healthcare initiatives and investments in medical technology. Regulatory frameworks are evolving to facilitate better healthcare delivery and patient outcomes. ### Rest of South America : Varied Growth Across Regions The Rest of South America holds a market value of 127.84, contributing about 19.6% to the overall regional market. Growth is driven by varying levels of healthcare infrastructure and awareness of NTM diseases across countries. Regulatory policies differ significantly, impacting market dynamics. Countries like Chile and Colombia are seeing increased investments in healthcare, while others face challenges in access to diagnostics and treatment. The competitive landscape includes both local and international players. ## Competitive Benchmarking The nontuberculous mycobacteria market in South America is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and Abbott Laboratories (US) are actively pursuing strategies that enhance their market presence. For instance, Thermo Fisher Scientific (US) focuses on developing advanced diagnostic solutions, which positions the company as a leader in the market. Meanwhile, Merck KGaA (DE) emphasizes its commitment to research and development, aiming to introduce novel therapeutic options. Abbott Laboratories (US) is leveraging its extensive distribution network to enhance accessibility to its products, thereby strengthening its competitive edge. Collectively, these strategies contribute to a dynamic environment where innovation and operational efficiency are paramount.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach not only enhances responsiveness to market demands but also mitigates risks associated with global supply chain disruptions. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set industry standards and drive technological advancements that smaller firms often follow. In October Roche Holding AG (CH) announced a strategic partnership with a local biotechnology firm to enhance its diagnostic capabilities in the region. This collaboration is expected to facilitate the development of tailored solutions for nontuberculous mycobacterial infections, thereby expanding Roche's product portfolio and reinforcing its market position. The strategic importance of this partnership lies in its potential to accelerate innovation and improve patient outcomes through localized solutions. In September BioMérieux SA (FR) launched a new rapid diagnostic test specifically designed for nontuberculous mycobacteria. This product aims to streamline the diagnostic process, reducing time to results significantly. The introduction of this test is likely to enhance BioMérieux's competitive positioning by addressing a critical need in the market for faster diagnostics, which is essential for timely treatment decisions. In August Hologic Inc. (US) expanded its product offerings by acquiring a small diagnostics company specializing in infectious diseases. This acquisition is anticipated to bolster Hologic's capabilities in the nontuberculous mycobacteria segment, allowing for a more comprehensive approach to disease management. The strategic move underscores Hologic's commitment to enhancing its portfolio and responding to the evolving needs of healthcare providers. As of November current trends in the nontuberculous mycobacteria market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostics. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in the future. ## Recent News & Developments The South America Nontuberculous Mycobacteria Market has experienced significant developments recently. In August 2023, Fujifilm announced the expansion of its microbiological diagnostic capabilities in Brazil, enhancing the detection and treatment of nontuberculous mycobacterial infections. In parallel, Merck KGaA has been increasing its collaboration with local research centers in South America for developing tailored diagnostic solutions, recognizing the rising incidence of nontuberculous mycobacterial diseases in the region. The growth potential of the market has attracted major players such as BD and Thermo Fisher Scientific, driving innovation in diagnostic technologies. Recent years have also witnessed a notable increase in investments towards Research and Development for improving diagnostic tools, with the market valuation expected to grow by 15 percent annually until 2025, fueled by rising health awareness and improved healthcare infrastructure throughout South America. Additionally, in July 2022, Roche acquired a local diagnostic company focused on infectious diseases, strengthening its position in the South American market as demand for advanced nontuberculous mycobacterial testing continues to rise. The increase in partnerships and collaborations among key stakeholders further emphasizes the growing significance of this market in public health initiatives across the region. ## Report Scope | MARKET SIZE 2024 | 747.84(USD Million) | | --- | --- | | MARKET SIZE 2025 | 760.55(USD Million) | | MARKET SIZE 2035 | 900.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 1.7% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Roche Holding AG (CH), BioMérieux SA (FR), Hologic Inc. (US), Qiagen N.V. (NL), Becton Dickinson and Company (US) | | Segments Covered | Class of Drugs | | Key Market Opportunities | Emerging diagnostic technologies enhance detection and treatment options in the nontuberculous mycobacteria market. | | Key Market Dynamics | Rising awareness of nontuberculous mycobacterial infections drives demand for advanced diagnostic and treatment solutions in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the overall market valuation for the South America nontuberculous mycobacteria market in 2024?** A: The overall market valuation was $747.84 Million in 2024. **Q: What is the projected market valuation for the South America nontuberculous mycobacteria market by 2035?** A: The projected market valuation for 2035 is $900.0 Million. **Q: What is the expected CAGR for the South America nontuberculous mycobacteria market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 1.7%. **Q: Which companies are considered key players in the South America nontuberculous mycobacteria market?** A: Key players include Thermo Fisher Scientific, Merck KGaA, Abbott Laboratories, Roche Holding AG, BioMérieux SA, Hologic Inc., Qiagen N.V., and Becton Dickinson and Company. **Q: What was the valuation of oral antibiotics in the South America nontuberculous mycobacteria market in 2024?** A: The valuation of oral antibiotics was $200.0 Million in 2024. **Q: How much did nebulized antibiotics contribute to the market in 2024?** A: Nebulized antibiotics contributed $297.84 Million to the market in 2024. **Q: What is the projected growth for IV antibiotics in the South America nontuberculous mycobacteria market by 2035?** A: The projected valuation for IV antibiotics is expected to reach $180.0 Million by 2035. **Q: What was the market valuation for anti-nausea drugs in 2024?** A: The market valuation for anti-nausea drugs was $100.0 Million in 2024. **Q: How does the market for nebulized antibiotics compare to oral antibiotics in 2024?** A: In 2024, nebulized antibiotics valued at $297.84 Million significantly outperformed oral antibiotics, which were valued at $200.0 Million. **Q: What are the anticipated trends for the South America nontuberculous mycobacteria market in the coming years?** A: Anticipated trends suggest steady growth, with the market expected to reach $900.0 Million by 2035, driven by key players and increasing demand. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-nontuberculous-mycobacteria-market-52627*